指南与共识造血干细胞移植与细胞治疗

儿童癌症及造血干细胞移植受者发热与中性粒细胞减少症管理指南:2017年更新

Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update.
指南 / 共识 · J Clin Oncol · 2017-05-01

国际儿童发热与中性粒细胞减少症指南小组采用GRADE方法更新临床实践指南,系统评价观察性研究和随机试验,针对初始评估、持续管理和经验性抗真菌治疗提出推荐;与2012版相比,主要变化包括高风险FN经验性治疗可选用第四代头孢菌素、细化高危侵袭性真菌病风险分层、调整生物标志物与影像学检查,以及低危IFD且持续FN患者弱推荐不启动经验性抗真菌治疗。

要点

  • 高风险FN经验性治疗可选用第四代头孢菌素。
  • 细化风险分层以定义高危侵袭性真菌病患者。
  • 低危IFD且持续FN患者弱推荐不启动经验性抗真菌治疗。

核心结论

  • 更新后的儿童FN指南推荐可能影响癌症及造血干细胞移植患儿的诊疗。

研究设计与样本

  • 国际儿童发热与中性粒细胞减少症指南小组为多学科多国专家组成,含一名患者倡导者。
  • 针对风险分层与评估问题,更新观察性研究的系统评价。
  • 针对治疗问题,系统评价任何用于儿童FN经验性管理的随机试验。
  • 采用GRADE方法制定强或弱推荐,并将证据等级分为高、中、低或极低。

主要发现

  • 推荐涉及儿童FN的初始表现、持续管理和经验性抗真菌治疗。
  • 与2012版FN指南的关键差异包括:高风险FN经验性治疗列出第四代头孢菌素。
  • 风险分层细化以定义高危侵袭性真菌病患者。
  • 持续FN中IFD评估的推荐生物标志物和影像学检查有变化。
  • 低危IFD且持续FN患者弱推荐不启动经验性抗真菌治疗。

关键数值与推荐

  • 高风险FN经验性治疗可选用第四代头孢菌素(原文未给出具体药物名称与剂量)。
  • 低危IFD且持续FN患者弱推荐不启动经验性抗真菌治疗。
  • 采用GRADE方法将推荐分为强或弱,证据等级分为高、中、低或极低(原文未逐条列出各推荐等级)。

临床怎么用

  • 原文未据此给出具体临床操作推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To update a clinical practice guideline (CPG) for the empirical management of fever and neutropenia (FN) in children with cancer and hematopoietic stem-cell transplantation recipients. Methods The International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and multinational group of experts in pediatric oncology and infectious diseases that includes a patient advocate. For questions of risk stratification and evaluation, we updated systematic reviews of observational studies. For questions of therapy, we conducted a systematic review of randomized trials of any intervention applied for the empirical management of pediatric FN. The Grading of Recommendation Assessment, Development and Evaluation approach was used to make strong or weak recommendations and to classify levels of evidence as high, moderate, low, or very low. Results Recommendations related to initial presentation, ongoing management, and empirical antifungal therapy of pediatric FN were reviewed; the most substantial changes were related to empirical antifungal therapy. Key differences from our 2012 FN CPG included the listing of a fourth-generation cephalosporin for empirical therapy in high-risk FN, refinement of risk stratification to define patients with high-risk invasive fungal disease (IFD), changes in recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and a weak recommendation to withhold empirical antifungal therapy in IFD low-risk patients with prolonged FN. Conclusion Changes to the updated FN CPG recommendations will likely influence the care of pediatric patients with cancer and those undergoing hematopoietic stem-cell transplantation. Future work should focus on closing research gaps and on identifying ways to facilitate implementation and adaptation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol. 2017. PMID: 28459614. doi:10.1200/JCO.2016.71.7017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。